Silencing Disease Genes in the Laboratory and the Clinic

Overview

Journal J Pathol

Specialty Pathology

Date 2011 Nov 10

PMID 22069063

Citations 200

Authors

Jonathan K Watts

David R Corey

Affiliations

Soon will be listed here.

Abstract

Synthetic nucleic acids are commonly used laboratory tools for modulating gene expression and have the potential to be widely used in the clinic. Progress towards nucleic acid drugs, however, has been slow and many challenges remain to be overcome before their full impact on patient care can be understood. Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) are the two most widely used strategies for silencing gene expression. We first describe these two approaches and contrast their relative strengths and weaknesses for laboratory applications. We then review the choices faced during development of clinical candidates and the current state of clinical trials. Attitudes towards clinical development of nucleic acid silencing strategies have repeatedly swung from optimism to depression during the past 20 years. Our goal is to provide the information needed to design robust studies with oligonucleotides, making use of the strengths of each oligonucleotide technology.

Citing Articles

Programmable mRNA therapeutics for controlled epigenomic modulation of single and multiplexed gene expression in diverse diseases.

ODonnell C, Farelli J, Belaghzal H, Chen J, Beech L, Sullivan J Nat Commun. 2025; 16(1):2517.

PMID: 40082450 PMC: 11906599. DOI: 10.1038/s41467-025-57920-5.

Evolution of antisense oligonucleotides: navigating nucleic acid chemistry and delivery challenges.

Ruchi R, Raman G, Kumar V, Bahal R Expert Opin Drug Discov. 2024; 20(1):63-80.

PMID: 39653607 PMC: 11823135. DOI: 10.1080/17460441.2024.2440095.

Investigational RNA Interference Agents for Hepatitis B.

Hui R, Mak L, Seto W, Yuen M BioDrugs. 2024; 39(1):21-32.

PMID: 39644435 PMC: 11750937. DOI: 10.1007/s40259-024-00694-x.

RNAi library screening reveals Gβ1, Casein Kinase 2 and ICAP-1 as novel regulators of LFA-1-mediated T cell polarity and migration.

Haap-Hoff A, Freeley M, Dempsey E, Dunican D, Bennett E, Triglia D Immunol Cell Biol. 2024; 103(1):73-92.

PMID: 39607284 PMC: 11688611. DOI: 10.1111/imcb.12838.

Clinical Applications of Antisense Oligonucleotides in Cancer: A Focus on Glioblastoma.

Khuu A, Verreault M, Colin P, Tran H, Idbaih A Cells. 2024; 13(22).

PMID: 39594617 PMC: 11592788. DOI: 10.3390/cells13221869.

References

Williams D, Benseler F, Eckstein F . Properties of 2'-fluorothymidine-containing oligonucleotides: interaction with restriction endonuclease EcoRV. Biochemistry. 1991; 30(16):4001-9. DOI: 10.1021/bi00230a027. View

Rudnick S, Swaminathan J, Sumaroka M, Liebhaber S, Gewirtz A . Effects of local mRNA structure on posttranscriptional gene silencing. Proc Natl Acad Sci U S A. 2008; 105(37):13787-92. PMC: 2544532. DOI: 10.1073/pnas.0805781105. View

Straarup E, Fisker N, Hedtjarn M, Lindholm M, Rosenbohm C, Aarup V . Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res. 2010; 38(20):7100-11. PMC: 2978335. DOI: 10.1093/nar/gkq457. View

Sczakiel G . Theoretical and experimental approaches to design effective antisense oligonucleotides. Front Biosci. 2000; 5:D194-201. DOI: 10.2741/sczakiel. View

Jearawiriyapaisarn N, Moulton H, Buckley B, Roberts J, Sazani P, Fucharoen S . Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther. 2008; 16(9):1624-9. PMC: 2671676. DOI: 10.1038/mt.2008.120. View

Garzon R, Marcucci G, Croce C . Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9(10):775-89. PMC: 3904431. DOI: 10.1038/nrd3179. View

Elbashir S, Lendeckel W, Tuschl T . RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001; 15(2):188-200. PMC: 312613. DOI: 10.1101/gad.862301. View

Pan Q, Shai O, Lee L, Frey B, Blencowe B . Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008; 40(12):1413-5. DOI: 10.1038/ng.259. View

Yin H, Moulton H, Seow Y, Boyd C, Boutilier J, Iverson P . Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet. 2008; 17(24):3909-18. PMC: 7108561. DOI: 10.1093/hmg/ddn293. View

10.

Sano M, Sierant M, Miyagishi M, Nakanishi M, Takagi Y, Sutou S . Effect of asymmetric terminal structures of short RNA duplexes on the RNA interference activity and strand selection. Nucleic Acids Res. 2008; 36(18):5812-21. PMC: 2566866. DOI: 10.1093/nar/gkn584. View

11.

Aartsma-Rus A, van Ommen G . Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA. 2007; 13(10):1609-24. PMC: 1986821. DOI: 10.1261/rna.653607. View

12.

Boese Q, Leake D, Reynolds A, Read S, Scaringe S, Marshall W . Mechanistic insights aid computational short interfering RNA design. Methods Enzymol. 2005; 392:73-96. DOI: 10.1016/S0076-6879(04)92005-8. View

13.

Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y . Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008; 26(4):431-42. DOI: 10.1038/nbt1396. View

14.

Nielsen P, Egholm M, Berg R, Buchardt O . Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science. 1991; 254(5037):1497-500. DOI: 10.1126/science.1962210. View

15.

Suwanmanee T, Sierakowska H, Lacerra G, Svasti S, Kirby S, Walsh C . Restoration of human beta-globin gene expression in murine and human IVS2-654 thalassemic erythroid cells by free uptake of antisense oligonucleotides. Mol Pharmacol. 2002; 62(3):545-53. DOI: 10.1124/mol.62.3.545. View

16.

Stewart A, Canitrot Y, Baracchini E, Dean N, Deeley R, Cole S . Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochem Pharmacol. 1996; 51(4):461-9. DOI: 10.1016/0006-2952(95)02220-1. View

17.

Montgomery R, Van Rooij E . Therapeutic advances in MicroRNA targeting. J Cardiovasc Pharmacol. 2010; 57(1):1-7. DOI: 10.1097/FJC.0b013e3181f603d0. View

18.

Srivastava P, Barman J, Pathmasiri W, Plashkevych O, Wenska M, Chattopadhyaya J . Five- and six-membered conformationally locked 2',4'-carbocyclic ribo-thymidines: synthesis, structure, and biochemical studies. J Am Chem Soc. 2007; 129(26):8362-79. DOI: 10.1021/ja071106y. View

19.

Paula D, Bentley M, Mahato R . Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA. 2007; 13(4):431-56. PMC: 1831859. DOI: 10.1261/rna.459807. View

20.

Dassie J, Liu X, Thomas G, Whitaker R, Thiel K, Stockdale K . Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol. 2009; 27(9):839-49. PMC: 2791695. DOI: 10.1038/nbt.1560. View